Kronos Bio Inc (NASDAQ:KRON) — Market Cap & Net Worth
Market Cap & Net Worth: Kronos Bio Inc (KRON)
Kronos Bio Inc (NASDAQ:KRON) has a market capitalization of $53.65 Million ($53.65 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21733 globally and #4869 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kronos Bio Inc's stock price $0.88 by its total outstanding shares 60969200 (60.97 Million). Also see Kronos Bio Inc asset portfolio for a full breakdown of the balance sheet.
Kronos Bio Inc Market Cap History: 2020 to 2025
Kronos Bio Inc's market capitalization history from 2020 to 2025. Data shows change from $1.82 Billion to $53.65 Million (-51.77% CAGR). Also see KRON cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Kronos Bio Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #627 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2077 of 3165 |
Weight: Kronos Bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kronos Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kronos Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Kronos Bio Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
5.88x
Kronos Bio Inc's market cap is 5.88 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $98.77 Million | $3.08 Million | -$129.29 Million | 32.03x | N/A |
| 2023 | $76.21 Million | $6.29 Million | -$112.67 Million | 12.12x | N/A |
| 2024 | $57.92 Million | $9.85 Million | -$86.08 Million | 5.88x | N/A |
Competitor Companies of KRON by Market Capitalization
Companies near Kronos Bio Inc in the global market cap rankings as of September 18, 2026. Review Kronos Bio Inc (KRON) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Kronos Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Kronos Bio Inc Historical Marketcap From 2020 to 2025
Between 2020 and today, Kronos Bio Inc's market cap moved from $1.82 Billion to $ 53.65 Million, with a yearly change of -51.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $53.65 Million | -7.37% |
| 2024 | $57.92 Million | -24.00% |
| 2023 | $76.21 Million | -22.84% |
| 2022 | $98.77 Million | -88.08% |
| 2021 | $828.57 Million | -54.50% |
| 2020 | $1.82 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Kronos Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $53.65 Million USD |
| MoneyControl | $53.65 Million USD |
| MarketWatch | $53.65 Million USD |
| marketcap.company | $53.65 Million USD |
| Reuters | $53.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kronos Bio Inc
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT in… Read more